Peptide pharmacology: Pioneering interventions for alcohol use disorder.

Alcohol use disorder (AUD) is a substantial public health issue, with few treatment choices and a high social cost. This review investigates the possibility of peptide pharmacology as a new treatment for AUD. Peptides, or short chains of amino acids, provide specific manipulation of neuronal pathways involved in addiction, such as the opioid, corticotropin-releasing factor (CRF), neuropeptide Y (NPY), and glutamate systems. Preclinical research has shown that peptide-based therapies can reduce alcohol intake, demand, and relapse in animal models of AUD. Opioid peptides like β-endorphin and enkephalins affect alcohol reward processing by interacting with µ, ∂, and κ opioid receptors. CRF peptides reduce stress-induced alcohol-seeking behavior by targeting the dysregulated CRF system. NPY and associated peptides reduce cravings and anxiety by regulating stress and emotional processing. Peptide-based therapies have strong translational potential, as evidenced by early clinical trial results. There are also challenges in converting preclinical discoveries into clinical practice, such as establishing the safety, tolerability, and effectiveness of peptide therapies in humans. Future initiatives include identifying new peptide targets, optimizing pharmacokinetics, and incorporating peptide-based therapies into established therapy methods. Overall, peptide pharmacology represents a potential prospect in AUD therapy, as it provides tailored therapies that address the complex neurobiological pathways that underpin addiction.